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Late presentation with HIV infection represents an ongoing and serious challenge to the control of the AIDS epidemic. Compared with patients who present early, patients who present late have higher rates of morbidity and mortality, and require a greater investment of time and resources from healthcare systems [1] . Agreement of a clear definition of late presentation will enable both accurate measurement of the progress made in reducing late presentation [2] and easier identification of successful HIV testing strategies [3] . Once late-presenting patients are diagnosed, their management can be complex, particularly if opportunistic infection is involved [4] .
European Working Group on late presentation
The recommendations contained in this supplement are the outcomes from a European Working Group on late presentation that was convened in Windsor, UK, for a 2-day workshop on 30-31 March 2009. A total of 51 European experts from 13 countries attended the meeting. The initial sessions of the workshop reviewed data available on late presentation in the four topics identified in this supplement: definition and epidemiology, medical and societal consequences, strategies for earlier testing and options for management. Following this, attendees were split into four breakout groups and each group reviewed draft statements and/or recommendations relevant to two of the topics. Revised versions of the statements and/or recommendations were then presented in a plenary session to be approved by all attendees.
In preparing this review, the meeting faculty reviewed the approved recommendations and, where appropriate, have provided an assessment of that recommendation. This assessment follows the convention of grading the recommendation as either strong (A), moderate (B) or optional (C), and the quality of supporting evidence as either results available from randomized controlled trials (I), results available from other published studies (II) or expert opinion (III). All recommendations included in this document were approved by ≥51% of meeting attendees. Instances where a recommendation or statement was approved by ≥51% of attendees but <75% are italicized and discussed further in the text.
Introduction
on an understanding that information on late presentation in Europe is not, at present, collected systematically or analysed rigorously. The lower approval score for statement S3, that older individuals in all risk groups are likely to present late, as a consequence of the fact that age is likely to increase the rate of disease progression, suggests that additional data on this risk factor are required.
Most existing guidelines [5] [6] [7] [8] recommend treatment initiation in all patients who present with CD4 + T-cell counts of <350 cells/µl or with an AIDS-defining condition. All such patients should therefore be understood to be presenting late and should receive antiretroviral therapy (ART) promptly (R2), an approach that is also supported by the HIV in Europe group [9] and by an observational analysis of the UK CHIC that evaluated the sensitivity and specificity of a range of definitions [10] . However, because of the evidence of worsening risks of clinical outcomes as baseline CD4 + T-cell counts decrease, patients who present with CD4 + T-cell counts <200 cells/µl should also receive immediate attention (R3). Such patients can be considered to be 'very late presenters' or, as discussed at the most recent HIV in Europe meeting [11] and in the UK CHIC publication [10] , patients with advanced HIV disease. These recommendations have implications for the design and implementation of strategies to reduce late presentation.
Medical and societal consequences of late presentation
The statements agreed for this topic are given in Table 2 . The risks of morbidity and mortality associated with late presentation are well-documented and reviewed by Moreno et al. [1] in this supplement. Patients who present late have a shorter life expectancy and are more likely to be affected by both AIDS and non-AIDS events.
The societal consequences of late presentation have been less thoroughly investigated, particularly in Europe. This is reflected by the lower approval score for statement S8 (Table 2 ; parts a and b). For both statements there is an absence of definitive studies. In particular, although some cost-effectiveness and resource-use studies looking at the burden imposed by late presentation specifically have been carried out in North America, there are very few such data available for Europe. Given the variation in healthcare systems across Europe, the collection of such data to determine the societal costs of late presentation should be a priority.
Earlier testing for HIV -how do we prevent late presentation?
The statements and recommendations agreed for this topic are given in Table 3 . As discussed by Yazdanpanah et al. [3] , the relative lack of data in this area has hampered the design and implementation of effective strategies to reduce late presentation. The agreed statements in this area represent the understanding of meeting attendees that late presentation can affect all patients in many settings.
Given the paucity of controlled studies, the recommendations in this topic are substantially based on discussion of attendees' experience with limited local schemes. 
Management of late-presenting patients with HIV infection
The statements and recommendations agreed for this topic are given in Table 4 . As described by Rockstroh et al. [4] , the challenges of managing patients who present late are predominantly associated with the poor immunological and virological status of these patients at the time of diagnosis, and the attendant risk of complications such as opportunistic infection. These factors affect the timing of initiation of ART in patients with certain opportunistic infections (for example, Pneumocystis pneumonia and tuberculosis). When an antiretroviral combination is selected, potential drug-drug interactions and concomitant comorbidities should be considered, along with the viral resistance profile. Rapidly establishing primary and secondary prophylaxis should also be a priority, although the extent to which it is possible will vary from case to case. For these reasons and others, physicians' judgement is central to the effective management of late-presenting patients.
The recommendations for this topic were more heavily debated than the others, and this is reflected in the lower approval rates for recommendations R14, R15, R16 and R19. To an extent this is a result of variations in treatment practice across Europe. In some countries, it is standard practice to initiate ART early in late-presenting patients with malignancies; in others, it is standard practice to delay the initiation of ART until after treatment for the malignancy is completed. The R6. Programmes to increase awareness of HIV risk should take into account local cultural resistance to, or scepticism of, HIV AIII diagnosis and treatment. R7. There is a need to improve awareness among patients that modern highly active antiretroviral therapy regimens are effective AIII and available free of charge. S11. HIV patients might present in various healthcare settings, with signs, symptoms and laboratory abnormalities that might be related to HIV, which create an opportunity for earlier HIV diagnosis. R8. There is a need to improve knowledge of HIV among all healthcare providers, including primary care physicians, and to provide AIII them with the skills to implement testing and information for appropriate referral. Other recommendations R9. HIV tests should be routinely offered as provider-initiated tests for antenatal services, patients seeking treatment at sexually AIII transmitted infection clinics, termination of pregnancy services, drug dependency programmes and those with tuberculosis, infectious hepatitis and possible HIV-related disease. R10. To reduce the barriers for HIV testing, services should be appropriate to patients' personal and cultural needs. AIII R11. Rapid test availability provides opportunities to test in various settings, including those that are community-based. AIII R12. HIV testing should be provided in community settings relevant to high-risk groups. AIII Table 3 . Statements and recommendations on earlier testing for HIV and preventing late presentation Statements were approved by ≥75% of attendees. Some recommendations in this topic were developed to directly support statements. This assessment follows the convention of grading the recommendation as strong (A), and the quality of supporting evidence as expert opinion (III).
this topic indicates a need for better data. In particular, for many antiretroviral drugs there are currently insufficient data on the additional risks associated with use in patients with low and very low CD4 + T-cell counts.
Conclusions
In terms of both its frequency and its consequences, late presentation with HIV infection remains a major clinical challenge in Europe. As this supplement has discussed, early diagnosis is essential to reduce the considerable effect of late presentation on patient health and wellbeing. ART should be administered at the right time and regimens should be carefully selected, taking into account potential toxicities, drug-drug interactions and viral resistance. More and better data are still needed to answer many questions. As recently highlighted by HIV in Europe, early testing for HIV infection is known to be an economically and medically effective strategy, but is underused across Europe [9] . Furthermore, although CD4 + T-cell counts are measured in most European countries there are many areas in which they are not routinely reported to surveillance and public health systems. Collecting this data, through local as well as national strategies, is essential if the effect of interventions to reduce late presentation is to be accurately measured.
In the US, HIV testing is routinely undertaken in some areas with HIV infection prevalence above a defined threshold value. In Europe, this strategy remains the subject of much debate, and is favoured in some countries but not others [12] . At the meeting of this European Working Group, a recommendation to consider routine testing in areas where the HIV prevalence is ≥1 per 1,000 individuals was discussed in detail, but ultimately not approved by 51% of delegates, and therefore is not included in this supplement. An alternative approach might be to encourage indicator disease-led testing, ensuring all patients presenting with an indicator disease in an area of moderate or high AII R21. In the absence of a genotypic resistance test prior to initiating treatment in a late-presenting patient, there is a rationale for BIII starting therapy with a boosted protease-inhibitor-based regime. R22. A patient who presents late has a higher likelihood of losing mutations and reverting to wild type, which should also be taken CIII into consideration when selecting treatment, and may warrant closer monitoring.
Table 4. Statements and recommendations on management of late-presenting patients with HIV infection
Italics indicate approval by <75% of attendees; all other statements were approved by ≥75% of attendees. This assessment follows the convention of grading the recommendation as strong (A), moderate (B) or optional (C), and the quality of supporting evidence as either results available from randomized controlled trials (I), results available from other published studies (II) or expert opinion (III). HAART, highly active antiretroviral therapy; IRIS, immune reconstitution inflammatory syndrome; OI, opportunistic infection.
HIV infection prevalence are tested [13] . This strategy might be a particularly useful way to encourage primary care practitioners and other non-HIV specialists to consider testing.
It is clear that much remains to be done; however, we hope that, along with work by HIV in Europe and other groups, the recommendations described here will contribute to greater understanding of the challenges of late presentation, to improved testing strategies that will increase early diagnosis and to the continuing efforts to reduce the spread of HIV infection.
